SAN DIEGO and VANCOUVER, British Columbia, May 23, 2017 /PRNewswire/ -- Sophiris Bio Inc.
(NASDAQ: SPHS) (the "Company" or "Sophiris"), a late stage clinical
biopharmaceutical company developing topsalysin (PRX302) for the
treatment of patients with urological diseases, today reported that
it has received the regulatory clearance for the diluent – the
medium in which topsalysin is diluted. Clinical sites can now begin
dosing eligible patients in a Phase 2b study in localized prostate
cancer.
About Sophiris
Sophiris Bio Inc. is a late-stage clinical biopharmaceutical
company developing topsalysin (PRX302) for the treatment of
patients with urological diseases. Topsalysin is in Phase 2
clinical development for the focal treatment of localized prostate
cancer as well as Phase 3 clinical development for the treatment of
the lower urinary tract symptoms of benign prostatic hyperplasia
(BPH). Topsalysin is a highly potent ablative agent that is
selective and targeted in that it is only activated by
enzymatically active PSA which is found in high concentrations in
the transition zone of the prostate and in and around prostate
tumor cells. More than 400 patients have received topsalysin, which
continues to appear to be safe and well tolerated. For more
information, please visit www.sophirisbio.com.
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. Some of the risks and uncertainties that
could cause actual results, performance or achievements to differ
include without limitation, risks associated with clinical
development, including the risk that the enrollment of the Phase 2b
study will not be completed when expected and that results will not
be available when expected and risks that the results of the Phase
2b study will not replicate the results of the completed Phase 2
study of topsalysin for the treatment of localized low to
intermediate risk prostate cancer or the study endpoint[s] will not
be achieved, and other risks and uncertainties identified by
Sophiris in its public securities filings with the SEC. All
forward-looking statements are based on Sophiris' current beliefs
as well as assumptions made by and information currently available
to Sophiris and relate to, among other things, anticipated
financial performance, business prospects, strategies, regulatory
developments, clinical trial results, market acceptance, ability to
raise capital and future commitments. Readers are cautioned not to
place undue reliance on these forward-looking statements, which
speak only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
Sophiris in its public securities filings; actual events may differ
materially from current expectations. Sophiris disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company Contact:
Peter Slover
Chief Financial Officer
(858) 777-1760
Corporate Communications Contact:
Jason Spark
Canale Communications
(619) 849-6005
jason@canalecomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sophiris-bio-provides-update-on-phase-2b-study-of-topsalysin-in-localized-prostate-cancer-300462697.html
SOURCE Sophiris Bio Inc.